HLX01 (rituximab biosimilar)
GPTKB entity
Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
biosimilar |
| gptkbp:activeIngredient |
gptkb:rituximab
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:China
|
| gptkbp:ATCCode |
L01XC02
|
| gptkbp:developedBy |
gptkb:Shanghai_Henlius_Biotech
|
| https://www.w3.org/2000/01/rdf-schema#label |
HLX01 (rituximab biosimilar)
|
| gptkbp:indication |
leukemia
chronic lymphocytic leukemia |
| gptkbp:marketedAs |
gptkb:Shanghai_Henlius_Biotech
|
| gptkbp:mechanismOfAction |
CD20-directed cytolytic antibody
|
| gptkbp:product |
gptkb:Rituxan
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:bfsParent |
gptkb:Shanghai_Henlius_Biotech
|
| gptkbp:bfsLayer |
7
|